PL1990410T3 - Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D - Google Patents
Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1DInfo
- Publication number
- PL1990410T3 PL1990410T3 PL07714709T PL07714709T PL1990410T3 PL 1990410 T3 PL1990410 T3 PL 1990410T3 PL 07714709 T PL07714709 T PL 07714709T PL 07714709 T PL07714709 T PL 07714709T PL 1990410 T3 PL1990410 T3 PL 1990410T3
- Authority
- PL
- Poland
- Prior art keywords
- cd1d
- immunotherapy
- pulsed
- expressing
- target antigen
- Prior art date
Links
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 title 2
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 title 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006045193 | 2006-02-22 | ||
| EP07714709.8A EP1990410B1 (en) | 2006-02-22 | 2007-02-21 | IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND |
| PCT/JP2007/053209 WO2007097370A1 (ja) | 2006-02-22 | 2007-02-21 | ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1990410T3 true PL1990410T3 (pl) | 2020-07-13 |
Family
ID=38437409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07714709T PL1990410T3 (pl) | 2006-02-22 | 2007-02-21 | Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100233215A1 (pl) |
| EP (2) | EP1990410B1 (pl) |
| JP (2) | JP5672647B2 (pl) |
| CY (1) | CY1122911T1 (pl) |
| DK (1) | DK1990410T3 (pl) |
| ES (2) | ES2774707T3 (pl) |
| HU (1) | HUE049283T2 (pl) |
| LT (1) | LT1990410T (pl) |
| PL (1) | PL1990410T3 (pl) |
| PT (1) | PT1990410T (pl) |
| SI (1) | SI1990410T1 (pl) |
| WO (1) | WO2007097370A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5428010B2 (ja) * | 2005-06-17 | 2014-02-26 | 独立行政法人理化学研究所 | Ｎｋｔ細胞の機能解析法 |
| LT1990410T (lt) * | 2006-02-22 | 2020-03-10 | Riken | Imunoterapija, panaudojant ląstelę, gebančią koekspresuoti tikslinį antigeną ir cd1d, ir kuri buvo aktyvinta cd1d ligandu |
| EP2199793A4 (en) * | 2007-09-10 | 2012-01-11 | Riken | METHOD FOR EVALUATING HUMAN DENDRITIC CELLS AND HUMAN-CELL IMMUNOTHERAPEUTICS |
| KR100995340B1 (ko) * | 2007-11-19 | 2010-11-19 | 재단법인서울대학교산학협력재단 | 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신 |
| EP2371945A4 (en) * | 2008-11-28 | 2013-01-16 | Riken | IMMUNOTHERAPY PROCEDURE WITH CD1d AND TARGETANT CO-EXPRESSIVE ALLO CELLS |
| EP2738253A4 (en) | 2011-07-29 | 2015-04-22 | Riken | CELL FOR USE IN IMMUNOTHERAPY WITH A MODIFIED NUCLEIC ACIDIC CONSTRUCTIVE FOR WILMS TUMORGEN PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING THIS CELL AND NUCLEIC ACIDIC CONCRETE SAID |
| US10316332B2 (en) | 2011-07-29 | 2019-06-11 | Riken | Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product |
| JP6687246B2 (ja) * | 2014-12-11 | 2020-04-22 | 国立研究開発法人理化学研究所 | 改変型免疫細胞、改変型免疫細胞の製造方法、およびこれらの利用 |
| EP3250608B1 (en) * | 2015-01-27 | 2024-08-21 | LAVA Therapeutics N.V. | Single domain antibodies targeting cd1d |
| JP7125760B2 (ja) | 2019-06-14 | 2022-08-25 | 国立研究開発法人理化学研究所 | 免疫系を賦活化する細胞および当該細胞を含む医薬組成物 |
| JP7537766B2 (ja) * | 2019-08-09 | 2024-08-21 | 国立研究開発法人理化学研究所 | 人工アジュバントベクター細胞と免疫賦活化剤との併用 |
| MX2022006716A (es) | 2019-12-02 | 2022-09-12 | Astellas Pharma Inc | Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer. |
| JP6912765B1 (ja) * | 2019-12-02 | 2021-08-04 | アステラス製薬株式会社 | 人工アジュバント細胞（ａＡＶＣ）を用いたがんの治療方法 |
| JP2023078487A (ja) * | 2020-04-08 | 2023-06-07 | アステラス製薬株式会社 | がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞 |
| JPWO2022230971A1 (pl) * | 2021-04-30 | 2022-11-03 | ||
| JPWO2024147357A1 (pl) * | 2023-01-06 | 2024-07-11 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3907698B2 (ja) | 1994-10-03 | 2007-04-18 | アメリカ合衆国 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
| US20040214783A1 (en) * | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| JP2002112780A (ja) | 2000-10-03 | 2002-04-16 | Keio Gijuku | ヒト膀胱癌抗原 |
| JP2004147649A (ja) | 2002-10-11 | 2004-05-27 | Kumamoto Technology & Industry Foundation | 頭頚部癌の抗原 |
| HU0301358D0 (en) * | 2003-05-14 | 2003-07-28 | Debreceni Egyetem | Novel use of ppargamma agonists |
| JP2005139118A (ja) | 2003-11-07 | 2005-06-02 | Ortho Mcneil Pharmaceut Inc | 腫瘍の治療のための細胞治療方法 |
| JP5002915B2 (ja) | 2004-07-01 | 2012-08-15 | 住友化学株式会社 | 光学活性なシクロプロパンカルボン酸エステル化合物の製造方法およびそれに用いる不斉銅錯体 |
| WO2007043630A1 (ja) * | 2005-10-06 | 2007-04-19 | Riken | 上気道粘膜下に投与されるｎｋｔ細胞刺激剤 |
| LT1990410T (lt) * | 2006-02-22 | 2020-03-10 | Riken | Imunoterapija, panaudojant ląstelę, gebančią koekspresuoti tikslinį antigeną ir cd1d, ir kuri buvo aktyvinta cd1d ligandu |
| US10316332B2 (en) * | 2011-07-29 | 2019-06-11 | Riken | Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product |
| JP6912765B1 (ja) * | 2019-12-02 | 2021-08-04 | アステラス製薬株式会社 | 人工アジュバント細胞（ａＡＶＣ）を用いたがんの治療方法 |
-
2007
- 2007-02-21 LT LTEP07714709.8T patent/LT1990410T/lt unknown
- 2007-02-21 ES ES07714709T patent/ES2774707T3/es active Active
- 2007-02-21 JP JP2008501739A patent/JP5672647B2/ja active Active
- 2007-02-21 ES ES11189797T patent/ES2780176T3/es active Active
- 2007-02-21 PL PL07714709T patent/PL1990410T3/pl unknown
- 2007-02-21 PT PT77147098T patent/PT1990410T/pt unknown
- 2007-02-21 EP EP07714709.8A patent/EP1990410B1/en active Active
- 2007-02-21 WO PCT/JP2007/053209 patent/WO2007097370A1/ja not_active Ceased
- 2007-02-21 DK DK07714709.8T patent/DK1990410T3/da active
- 2007-02-21 SI SI200732144T patent/SI1990410T1/sl unknown
- 2007-02-21 EP EP11189797.1A patent/EP2441468B1/en active Active
- 2007-02-21 HU HUE07714709A patent/HUE049283T2/hu unknown
- 2007-02-21 US US12/280,305 patent/US20100233215A1/en active Pending
-
2013
- 2013-04-15 JP JP2013084903A patent/JP5673723B2/ja active Active
-
2020
- 2020-04-06 CY CY20201100322T patent/CY1122911T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1990410B1 (en) | 2020-01-08 |
| EP1990410A4 (en) | 2009-08-26 |
| PT1990410T (pt) | 2020-03-03 |
| WO2007097370A1 (ja) | 2007-08-30 |
| SI1990410T1 (sl) | 2020-07-31 |
| HUE049283T2 (hu) | 2020-09-28 |
| JPWO2007097370A1 (ja) | 2009-07-16 |
| US20100233215A1 (en) | 2010-09-16 |
| CY1122911T1 (el) | 2021-10-29 |
| EP2441468A2 (en) | 2012-04-18 |
| ES2780176T3 (es) | 2020-08-24 |
| DK1990410T3 (da) | 2020-04-06 |
| EP1990410A1 (en) | 2008-11-12 |
| EP2441468A3 (en) | 2012-10-17 |
| JP5673723B2 (ja) | 2015-02-18 |
| EP2441468B1 (en) | 2020-01-08 |
| ES2774707T3 (es) | 2020-07-22 |
| JP5672647B2 (ja) | 2015-02-18 |
| JP2013212107A (ja) | 2013-10-17 |
| LT1990410T (lt) | 2020-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1990410T3 (pl) | Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D | |
| CY2020021I2 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης | |
| CY2021009I1 (el) | Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι χρησης αυτων στην αντιμετωπιση φλεγμονωδων νοσων | |
| PL2358756T3 (pl) | Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9 | |
| IL210768B (en) | Antibodies targeting complement protein c5 and compositions comprising them | |
| EP2371333A4 (en) | THIN CLEANER ARTICLE | |
| DK2222706T3 (da) | Antibodies against human nkg2d and uses thereof | |
| BRPI0819909A2 (pt) | anticorpos antimesotelina e usos dos mesmos | |
| PT2427212T (pt) | Anticorpos anti-cd100 e métodos para utilização dos mesmos | |
| PT2424896E (pt) | Anticorpos anti-ceacam1 e métodos de utilização dos mesmos | |
| BRPI0914319A2 (pt) | anticorpos estáveis e solúveis que inibem tnfalfa | |
| BRPI0821110A2 (pt) | Anticorpo anti nr-10 e uso do mesmo | |
| PL3042917T3 (pl) | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie | |
| PL2942355T3 (pl) | Nie-hemolityczne białka fuzyjne llo i ich zastosowanie | |
| BRPI0716300A2 (pt) | Artigo e mistura | |
| DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
| PL1824887T3 (pl) | Przeciwciało cytotoksyczne skierowane przeciwko proliferacjom krwiotwórczych komórek limfatycznych typu B | |
| PL2437051T3 (pl) | System pseudo dwuenergetyczny i metoda identyfikacji materiałów z wykorzystaniem podpróbkowania | |
| BRPI0906478A2 (pt) | anticorpo anti-nr10 e uso do mesmo | |
| SE0802254L (sv) | Stoppsystem och stoppmetoder | |
| IL236516B (en) | Antibodies and compositions comprising them for treatment of cancer | |
| IT1394876B1 (it) | "mezzi per la duplicazione di una chiave codificata elettronicamente e relativo procedimento di duplicazione" | |
| BRPI0816789A2 (pt) | Goji e inflamação | |
| BRPI0814127A2 (pt) | Polipeptídeos imunegênicos e anticorpos monoclonais | |
| DK2310042T3 (da) | Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi |